Niagen Bioscience offers discounted longevity-platform upside if injectables, skincare, and NB4168 offset intensifying NMN commoditization and ATM dilution risk.
Overview
Niagen Bioscience, formerly ChromaDex, has evolved from an analytical reference-standards supplier into a cellular-health and healthy-aging company commercializing patented nicotinamide riboside across Consumer Products, Ingredient Technology, and Pharmaceuticals & Clinical Solutions. Its differentiation is supported by more than 45 human clinical trials, over 500 published studies, more than 100 patents, and the first official USP monograph for NR chloride. **The core business is profitable and growing, but near-term economics are pressured by generic NMN competition and launch spending.** Q1 2026 sales rose 3% to $31.5 million, or 5% on a normalized basis excluding the divested segment, while e-commerce increased 14% to $19.2 million. Gross margin was 63.5%, but adjusted EBITDA fell to $3.8 million from $4.9 million as marketing and clinical investments increased. The balance sheet held $66.5 million of cash and zero debt. Management reaffirmed 10%–15% full-year revenue growth guidance. **The upside case depends on scaling injectables, NanoCloud skincare, and NB4168.** The stock trades at 1.6x EV/revenue and 14.9x P/E versus peer averages of 2.5x and 18.8x, while analysts maintain $9.00–$12.00 targets.